Mainline Biosciences Raises RMB 100M in Series A Financing for Peptide Drugs
Mainline Biosciences, a polypeptide drug developer based in Zhongshan, has reportedly raised close to RMB...
Biotech
Sumitomo Dainippon Partners with Profex to Promote Antipsychotics in China
Japan-based Sumitomo Dainippon Pharma Co., Ltd has announced a partnership with Profex, a trade company...
Organon Signs MOU with China’s National Health Commission at CIIE
Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that...
Ascletis Pharma Presents Phase I Study Results for ASC43F at AASLD
China-based Ascletis Pharma Inc. (HKG: 1672) made a poster presentation detailing the abstract of a...
CIIE: Bo’ao Lecheng Zone Announces Partnerships with Multinationals
The 5th China International Import Expo (CIIE) saw the Bo’ao Lecheng Medical Tourism Pilot Zone...
Novatim Immune Therapeutics Raises RMB 500M in First Financing Round
China-based tumor immunotherapy developer Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has reportedly raised close to...
Fosun Pharma Terminates Equity Transfer Deal with OncoCare Medical
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the termination of...
Antengene’s CD73 Inhibitor ATG-037 Greenlit for Phase I Study by NMPA
China-based Antengene Corporation Limited (HKG: 6996) has announced receiving approval from the National Medical Products...
Ascletis Files IND Application for COVID-19 Oral Inhibitor ASC11 with FDA
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that the Investigational New Drug (IND) application...
Antengene’s ATG-017 Gets FDA Approval for Phase I Clinical Study
Antengene Corporation has announced receiving approval from the US Food and Drug Administration (FDA) to...
Shandong Buchang Partners with REMD Bio for Bispecific Antibody Development
China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) has announced a co-development and licensing agreement...
Zhejiang Medicine’s ARX788 Advances to Phase II Study for HER2-Positive Cholangiocarcinoma
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) has received approval from the National Medical Products...
Sanofi’s Q3 Sales Rise 9% on Dupixent and Flu Vaccine
French pharmaceutical major Sanofi (NASDAQ: SNY) released its Q3 2022 financial report, recording EUR 12.482...
Novartis’ Cosentyx Gains Approval for New Doses in China
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving marketing approval for two new specifications...
XtalPi Partners with Janssen to Accelerate Drug Discovery
China-based XtalPi, Inc. has announced a research collaboration with Janssen Pharmaceutica NV, one of the...
Innovent’s CLDN18.2 ADC IBI343 Begins Phase I Trial in Australia
Innovent Biologics Inc. (HKG: 1801) has announced the first subject dosing in a Phase I...
Ascletis Signs Pact with Pfizer China for Ritonavir Tablets
Ascletis Pharma Inc. (HKG: 1672) announced that its wholly-owned subsidiary Ascletis Pharmaceuticals Co., Ltd has...
Eli Lilly Cancels Licensing Deal for Fosun Pharma’s FCN-338
Shanghai Fosun Pharma (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its US partner...
Salubris Partners with Alpha Molecular for AI-Driven Obesity Drug Development
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has entered into a partnership with compatriot...
RemeGen Reports 397.47% YOY Revenue Growth in Q3 2022
China-based pharma firm RemeGen (HKG: 9995) released its Q3 2022 financial report, showing significant growth...